[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adhd---attention-deficit-disorder-with-hyperactivity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adhd---attention-deficit-disorder-with-hyperactivity":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,52,136,164,189,216,240,265,292,325,352,385,409,434,456,484,514,537,556,589,623,645,676],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100582242","acupuncture-for-adhd-acupoint-data-mining-clinical-effectiveness-and-interviews-to-explore-treatment-outcomes-100582242",false,"NCT06860763","Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.","Clinical Study on Acupuncture Treatment for Attention Deficit Hyperactivity Disorder.","ACU-ADHD","Inclusion Criteria:\n\nPatients will be considered for enrolment if they meet the criteria of:\n\n* A confirmed diagnosis of ADHD based on the DSM-5 criteria for ADHD (Western medical diagnosis) and in accordance with the ADHD Chinese Medicine Clinical Trial Design and Evaluation Technical Guidelines.\n* Aged between 6 and 12 years.\n* No use of any other pharmacological treatments (both Western and traditional Chinese medicine) within the two weeks prior to the start of the study.\n* An IQ score of greater than 80, as determined by the Raven's Progressive Matrices test.\n* The participant has not participated in any other clinical trials.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n* Do not meet the inclusion criteria\n* Have comorbid psychiatric disorders, severe medical or psychiatric conditions that may interfere with the study (e.g., epilepsy, severe anxiety), pervasive developmental disorders, intellectual disability, or a history of suicidal or self-harming behavior\n* Have participated in any other drug clinical trials within the past 3 months.\n* Have severe comorbid conditions such as cardiovascular, hepatic, renal, or hematologic diseases.\n* Have any other conditions that the researchers believe may interfere with the assessment of treatment efficacy or safety.","ALL","6 Years","12 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the efficacy of acupuncture as a treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12 years. Using a mixed-methods approach, the research will triangulate data from acupoint data mining, treatment outcomes assessment, and patient perspectives to provide a comprehensive analysis of acupuncture's potential therapeutic benefits for ADHD.\n\nThis prospective cohort study will recruit children diagnosed with ADHD, assigning them to receive either acupuncture combined with traditional Chinese herbal treatment or herbal treatment alone. Quantitative assessments using the the SNAP-IV, Conners 3-P, BRIEF-2, PedsQL™ 4.0 Generic Core Scales, PSQI and CGI that will be complemented by qualitative interviews to capture nuanced patient experiences and treatment outcomes.\n\nThe study will span 12 months, commencing on March 1st, 2025 with an expected completion by February 28th, 2026. By integrating quantitative assessments with qualitative insights, it aims to provide comprehensive evidence on acupuncture's role in ADHD management. Findings may inform clinical guidelines and enhance patient-centered care approaches.",[28,29,30,31,32,33],"Acupuncture","ADHD - Attention Deficit Disorder With Hyperactivity","Children","Interview","Executive Functioning","Quality of Life (QOL)",[28,35,36,31,37,38],"ADHD","Executive functioning","TCM","PedsQL","RECRUITING","2026-06-21",{"date":42,"type":43},"2026-06-23","ACTUAL",{"date":45,"type":43},"2024-10-15",{"date":47,"type":22},"2027-01-31",{"name":49,"class":50},"The Third Affiliated Hospital of Beijing University of Chinese Medicine","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":110,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":51},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"17 Years","99 Years",{"count":64,"type":22},1000000,[25],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[68,69,70,71,29,35,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[111,112,113,114,115,116,117,118,119,120,121,122,123,124,125],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","NOT_YET_RECRUITING","2026-06-16",{"date":129,"type":43},"2026-06-22",{"date":131,"type":22},"2026-08-01",{"date":133,"type":22},"2028-12-31",{"name":135,"class":50},"Veterans Recovery Network Inc.",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":51},"100643833","evaluation-of-the-relationship-between-medication-eye-movements-and-autonomic-nervous-system-ans-functions-in-children-and-adolescents-with-adhd-100643833","NCT07634809","Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System (ANS) Functions in Children and Adolescents With ADHD","Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System Functions in Children and Adolescents With ADHD","POP-Eye\u002FANSA","Inclusion Criteria:\n\n* ages of 6 -17\n* diagnosis of ADHD and agreed to medication administration in accordance with the clinic's procedures.\n\nExclusion Criteria:\n\n* diagnoses of arrhythmia, cardiovascular disease, or current substance use\n* concurrent use of non-steroidal asthma medications or beta-blockers\n* the inability to complete study participation before the participant's 18th birthday.\n* severe motor impairments and visual impairments that prevent participation in eye-tracking measurements.\n* caffeine intake within 4 hours prior to HRV and eye-tracking measurements",{"count":145,"type":22},150,"OBSERVATIONAL","An increasing number of children are being diagnosed with ADHD, and the demand for ADHD medication has been rising. Although ADHD medication is often effective, this is unfortunately not the case for all children and adolescents with ADHD; furthermore, the majority of those who use the medication experience side effects of some kind. There are currently no known factors that are clearly linked to whether ADHD medications will be effective or cause significant side effects. The healthcare system therefore has limited ability to provide recommendations on ADHD medication at the individual level, which means that most children and adolescents with ADHD try medication. Studies show that 35% of children aged 4-11 and 53% of 12-17-year-olds discontinue ADHD medication within a year. Perhaps these children and adolescents could have avoided fruitless treatment attempts if the healthcare system had been able to provide better recommendations regarding when ADHD medications are most likely to be effective and tolerable treatment options. This, combined with reports of rising mental health issues and an avalanche-like increase in demand for child and adolescent psychiatric services, makes it particularly urgent to develop methods for offering effective interventions to the right patients as specifically as possible.\n\nPrevious studies have not consistently identified factors (neither genetic nor other factors such as gender, age, symptom severity, symptom profile, or comorbidities) that are linked to the efficacy or side effects of ADHD medications.\n\nIn this project, we will investigate whether the efficacy and side effects of ADHD medications are linked to eye movements or activity within the autonomic nervous system. The autonomic nervous system is the part of our nervous system that is not under our conscious control. It controls many bodily functions such as pupil size, heart rate, blood pressure, and reactions to stress.\n\nEye and pupil movements are measures of where an individual's attention is directed and how activated the brain is. ADHD is a condition in which the individual has difficulty regulating attention and activity. Therefore, there may be reason to believe that eye movements could be significant in the treatment of ADHD, even though this has never been studied before. Nor has the connection between the autonomic nervous system and the effects of ADHD medications been studied previously, even though changes in heart rate and blood pressure are among the common side effects of ADHD medications.\n\nWe will invite children and adolescents who are about to begin ADHD medication. Before they start taking the medication, we will measure eye movements, pupil dilation, and the pupil's reaction to light using so-called eye-tracking technology. This is done by having the child or adolescent look at a screen and follow certain instructions while the pupil's movements are measured. We will also measure heart rate variability, i.e., how much the pulse varies, which can be done by continuously measuring the pulse for 10 minutes. We will investigate whether there is a correlation between the characteristics of these eye movement, pupil, and heart factors before medication begins and the extent to which the medication produces effect and side effects. We will also analyze how these factors are affected by the medication.\n\nThe advantage of these factors is that they can be measured without causing pain. Furthermore, they are objective because they measure time and distance and are therefore not dependent on anyone's personal perceptions, as is so often the case with the rating scales otherwise used in psychiatry.\n\nIf we can identify correlations between eye movements and activity in the autonomic nervous system and how ADHD medications affect children and adolescents with ADHD, there is a possibility that this could be used to provide better recommendations regarding ADHD medication. Many children could then be recommended other interventions first and avoid unnecessary and unpleasant drug treatments.",[29],[150,151,152,153,154],"Attention deficit hyperactivity disorder (ADHD)","eye movement","autonomic nervous system activity","medication effects","children and adolescents","2026-06-02",{"date":157,"type":43},"2026-06-09",{"date":159,"type":43},"2026-04-10",{"date":161,"type":22},"2028-11",{"name":163,"class":50},"Umeå University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100627066","comorbidity-between-attention-deficit-hyperactivity-disorder-and-fibromyalgia-100627066","NCT07443800","Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia","Comorbidity Between Attention Deficit Hyperactivity Disorder (ADHD) and Fibromyalgia: Cross-prevalence in Patients Treated for ADHD Who Are naïve to Methylphenidate, ADHD Treated With Methylphenidate, or Fibromyalgia, and Associated Metabolomic Factors","HYPERPAIN","Inclusion Criteria:\n\nFor patients with fibromyalgia :\n\n* Men or women aged 18 or over\n* Diagnosis of fibromyalgia\n* Affiliated with a social security scheme\n* Having signed an informed consent form\n\nFor patients with ADHD treated with methylphenidate\n\n* Men or women aged 18 or over\n* ADHD diagnosis\n* Current treatment with extended-release methylphenidate for at least 1 month, with stable dosage for at least 2 weeks\n* Affiliated with a social security scheme\n* Having signed an informed consent form\n\nFor patients with ADHD but not treated with methylphenidate\n\n* Men or women aged 18 or over\n* ADHD diagnosis\n* Affiliated with a social security scheme\n* Having signed an informed consent form\n\nExclusion Criteria:\n\n* For patients with fibromyalgia: existence of another condition explaining chronic pain\n* Severe cognitive impairment\n* Difficulties in understanding self-administered questionnaires\n* Difficulties in assessing pain intensity\n* Acute psychiatric disorder impacting the validity of self-report questionnaire data collection\n* Inability to take biological samples\n* Persons covered by Articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, women in labor, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, persons subject to legal protection measures: guardianship or curatorship).","18 Years","100 Years",{"count":175,"type":22},100,[25],"The overall objective of the research project presented here is to assess the prevalence of fibromyalgia in patients being treated for ADHD, the prevalence of ADHD in patients being treated for fibromyalgia, and the neurobiological correlates of ADHD-fibromyalgia comorbidity.",[29,179,180],"Fibromyalgia (FM)","Chronic Pain",{"date":182,"type":43},"2026-06-04",{"date":184,"type":22},"2026-07-01",{"date":186,"type":22},"2028-07-01",{"name":188,"class":50},"University Hospital, Tours",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":19,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100639417","retail-grade-weighted-blanket-effectiveness-on-adhd-related-sleep-disturbances-bead-100639417","NCT07588659","Retail-Grade Weighted Blanket Effectiveness on ADHD-related Sleep Disturbances (BEAD)","Retail-Grade Weighted Blanket Effectiveness on ADHD-related Sleep Disturbances - The Sweet BEAD Trial","Sweet BEAD","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Age 5-12 years.\n3. Diagnosis of ADHD according to ICD-10 code F90.0, F90.1, F90.9 or F98.8.\n4. Participated in a usual care sleep hygiene program managed by clinicians within 6 months prior to enrollment.\n5. If on ADHD medication or\u002Fand melatonin\u002Fsleep medication the dose must be stable, at least two weeks prior to enrollment.\n6. The child and caregiver have adequate mastery of the Danish language.\n\nExclusion Criteria:\n\n1. Have used any type of weighted blanket within a 3-month period.\n2. Any diagnosed diseases that markedly compromises the participant's ability to adhere to the intervention (like severe or deep mental retardation, severe underweight, chronic respiratory or circulatory conditions, surgical implants, osteoporosis).\n3. Another member of the household currently or previously enrolled in the Sweet Dreams Trial or the Sweet BEAD trial.","5 Years",{"count":175,"type":22},[25],"The goal of this clinical trial is to investigate if a commercially available (retail-grade) weighted blanket can improve sleep in children with Attention Deficit Hyperactivity Disorder (ADHD) and sleep disturbances. 100 children will be enrolled in the study. The location of the intervention is at Frederiksberg Hospital and Odense University Hospital in Denmark. The main objectives are:\n\n* Does using a retail-grade weighted blanket increase total sleep time (TST)?\n* Does it help children fall asleep faster, wake up fewer times at night, and sleep more efficiently overall?\n* Does better sleep relate to changes in daily functioning, ADHD symptoms, parental stress, and child well-being?\n* Do adverse events occur while children use retail-grade weighted blankets?\n\nThis is a single-group, open-label study. All participants receive a weighted blanket, and researchers compare each child's sleep before and after the 4-week blanket intervention period.\n\nWho can take part:\n\nChildren aged 5 to 12 years who have a confirmed ADHD diagnosis, and also experience sleep disturbances. Children must have completed a usual-care sleep hygiene program within the last 6 months. if they use ADHD medicine or sleep medication the dosage must be stable for at least two weeks before enrolling. Children who used any type of weighted blanket within the last three months, or have health conditions that make blanket use unsafe, cannot take part in the trial.\n\nWhat will happen:\n\nParticipation lasts about seven weeks, including measurements before and during the weighted blanket intervention period.\n\nParticipants will:\n\n* Attend a baseline visit (in person or online) where a caregiver gives consent and receives instructions.\n* Wear a small sleep monitor (actigraphy) on the non-dominant wrist for 1 week before starting the blanket\n* Attend an intervention visit to try the weighted blanket options and choose the most fitting weighted blanket for their sensory needs.\n* Use the weighted blanket every night for four weeks. During the day, the child will also use the blanket for about 10 minutes while sitting and relaxing.\n* Wear the sleep monitor again during the last two weeks of the 4-week blanket intervention period.\n* Receive a short follow-up phone call about two weeks after starting the blanket intervention period to ask about blanket use and reminding the initiation of the second actigraphy period.\n* A caregiver will receive a daily text message to report whether the blanket was used (day and\u002For night).\n* Complete questionnaires that are sent to them at the end of trial. A final end of trial phone call is completed where the caregiver will be asked if the child has had other treatments or change in their medication usage in the trial period.\n\n  2 years follow-up: Researchers may contact families again two years after the blanket intervention period to repeat key questionnaires. Researchers will also look at selected long-term outcomes in health and education registers at two and five years after the end of the intervention period, if agreed upon.\n\nOutcome Measures:\n\nThe primary outcome is the change in TST measured by actigraphy from baseline to the end of the 4-week intervention period. Secondary outcomes include other actigraphy sleep measures (time to fall asleep, number of awakenings, wake time after falling asleep, and sleep efficiency) and questionnaire scores on functioning, ADHD symptoms, parental stress, sensory processing, and child well-being\u002Fquality of life. Researchers will also record adverse events and serious adverse events during the enrollment period.",[29],[203,204,205,30,206],"Weighted Blanket","Sleep Disturbances","Sleep","Psychiatry","2026-05-21",{"date":209,"type":43},"2026-05-27",{"date":211,"type":22},"2026-05-20",{"date":213,"type":22},"2029-05",{"name":215,"class":50},"University Hospital Bispebjerg and Frederiksberg",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":51},"100639144","phase-4-medication-treatment-of-adhd-in-pediatric-epilepsy-100639144","NCT07594652","Medication Treatment of ADHD in Pediatric Epilepsy","USE of JORNAY PM® to TREAT ADHD in PEDIATRIC EPILEPSY","Inclusion Criteria:\n\n* Inclusion criteria:\n\n  * Established diagnosis of epilepsy that requires treatment with anti-seizure medication.\n  * No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.\n  * Diagnosis of ADHD with functional impairment.\n  * Good general health as determined by medical history and physical examination, including stable vital signs.\n  * Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.\n\nExclusion Criteria:\n\n* • Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®\n\n  * Active substance abuse or dependence within 30 days of enrollment\n  * Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months\n  * DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.\n  * Current use of stimulants to treat ADHD\n  * Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.\n  * Unstable cardiac illness such as arrythmias or cardiomyopathy.\n  * Participation in a previous experimental drug study within 30 days of baseline visit.\n  * Estimated IQ\\\u003C70 as indicated by clinical assessment to the degree that rating scales may be invalid\n  * Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures",{"count":224,"type":22},25,[226],"PHASE4","This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.",[29],[35,230],"epilepsy","2026-05-15",{"date":233,"type":43},"2026-05-19",{"date":235,"type":22},"2026-05",{"date":237,"type":22},"2030-12",{"name":239,"class":50},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":51},"100590762","advancing-identification-of-circadian-delay-in-adhd-youth-associations-with-clinical-heterogeneity-and-cognition-100590762","NCT06971640","Advancing Identification of Circadian Delay in ADHD Youth: Associations With Clinical Heterogeneity and Cognition","CIRCA","Inclusion Criteria:\n\n1. Child ages 6-9\n2. Meet criteria for a primary psychiatric diagnosis of DSM-5 ADHD, any presentation\n3. Intellectual functioning \\>80\n4. Healthy (i.e., no major medical problems)\n5. If applicable, willingness to suspend use of melatonin during the study period\n\nExclusion Criteria:\n\n1. Meet DSM-5 criteria for psychosis, bipolar, or autism spectrum disorders\n2. Diagnosis of occult sleep disorders, including sleep apnea or restless leg syndrome\n3. Medication for sleep other than melatonin\n4. Plans to initiate stimulant medication during the study period","9 Years",{"count":249,"type":22},250,"The purpose of this study is to better understand sleep and circadian functioning in children with ADHD using home-based measures, parent report, and a lab based melatonin assessment. Investigators will also examine how sleep relates to psychiatric health and cognition among children with ADHD. The investigator for this study is Dr. Jessica Lunsford-Avery from the Department of Psychiatry.",[29,35],[35,253,254,255],"attention deficit disorder with hyperactivity","circadian rhythm","dim light melatonin onset","2026-05-04",{"date":258,"type":43},"2026-05-05",{"date":260,"type":43},"2025-05-28",{"date":262,"type":22},"2029-11",{"name":264,"class":50},"Duke University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":60,"sex":17,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":289,"leadSponsor":290,"locationsCount":51},"100636799","biomarkers-of-asdadhd-and-factors-affecting-anxiety-and-depression-in-children-and-young-adults-100636799","NCT07570381","Biomarkers of ASD\u002FADHD and Factors Affecting Anxiety and Depression in Children and Young Adults","Biomarker Discovery for Predicting Autism Spectrum Disorder and Attention\u002FHyperactivity Disorders, and Identification of Environmental Factors Influencing Anxiety and Depression in Children, Adolescents, and Young Adults","PUREMIND-OS","OS1 Inclusion Criteria:\n\n* Infants born very preterm (\\\u003C32 weeks) or extremely preterm (\\\u003C28 weeks); or\n* Term-born infants with documented perinatal asphyxia and hypoxic-ischaemic encephalopathy (HIE); or\n* Term-born infants with no risk factors (comparison group).\n* Must be ≤12 months corrected age at enrolment.\n\nOS1 Exclusion Criteria:\n\n* Syndromic, chromosomal, or known genetic conditions.\n* Motor impairments that would prevent participation in psychometric or neurophysiology assessments.\n\nOS2 Inclusion Criteria:\n\n* Individuals aged 5-25 years.\n* Clinical diagnosis of ASD, ADHD, or Developmental Coordination Disorder (DCD).\n* Able to participate in scheduled assessments.\n\nOS2 Exclusion Criteria:\n\n* Severe motor impairments that limit psychometric assessment.\n* Diagnosis of schizophrenia, due to confounding neurocognitive effects.","6 Months","25 Years",{"count":276,"type":22},800,"The PUREMIND OS1\u002FOS2 study is a multinational, prospective, longitudinal observational study designed to identify early neurophysiological, biological, environmental, and psychosocial markers associated with neurodevelopmental and mental health conditions from infancy through young adulthood.\n\nObservational Study 1 (OS1) follows infants and toddlers at high risk for Autism Spectrum Disorder (ASD) and Attention-Deficit\u002FHyperactivity Disorder (ADHD) to discover biomarkers predictive of later clinical diagnosis, using EEG, fNIRS, psychometric assessments, and biological samples.\n\nObservational Study 2 (OS2) includes children, adolescents, and young adults with ASD, ADHD, or Developmental Coordination Disorder (DCD) to identify environmental and biological factors causally linked to anxiety and depression symptoms, and to support the development of personalised criteria for evidence-based interventions.\n\nApproximately 800 participants will be recruited across 10 international clinical sites. The study aims to generate multi-domain data to support predictive modelling and inform future personalised mental-health prevention strategies across childhood and young adulthood.",[29,279,280],"Autism Spectrum Disorder (ASD)","Developmental Coordination Disorder (DCD)",[282,283,284],"Attention Deficit Disorder with Hyperactivity","Autism spectrum disorder","Developmental Coordination Disorder","2026-04-29",{"date":287,"type":43},"2026-05-06",{"date":131,"type":22},{"date":133,"type":22},{"name":291,"class":50},"University of Exeter",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":300,"minAge":172,"maxAge":173,"enrollmentInfo":301,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":303,"conditions":304,"keywords":310,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":51},"100634507","mocha-embedded-inpatient-mental-health-care-for-high-risk-perinatal-patients-100634507","NCT07540585","MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients","MOCHA Protocol: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients","MOCHA","Inclusion Criteria:\n\n* 18 years old or older\n* Pregnant (or recently have given birth) at any gestational age\n* Must have experienced at least one adverse pregnancy outcome\n* Admitted for an extended inpatient stay\n* English speaking\n\nExclusion Criteria:\n\n* Under 18 years old\n* Not currently pregnant or past one year postpartum\n* Not experienced at least one adverse pregnancy outcome\n* Not admitted for an extended inpatient stay at RMT","FEMALE",{"count":302,"type":22},50,"Pregnant and postpartum patients hospitalized for medical complications experience high rates of depression, anxiety, and trauma-related symptoms, yet access to timely psychiatric care during obstetric hospitalization is limited. Project MOCHA integrates early mental health screening, trauma-informed psychotherapy, and structured follow-up into routine inpatient maternity care for individuals at elevated clinical risk.\n\nThis single-arm implementation study examines the feasibility, acceptability, and fidelity of delivering a Collaborative Mental Health Care Program within a high-risk obstetric inpatient setting. The program includes brief inpatient psychotherapy, symptom monitoring, and post-discharge follow-up over three months. Preliminary changes in depression, anxiety, attention-deficit hyperactivity disorder, and posttraumatic stress symptoms will be assessed to inform future effectiveness trials and broader health system integration.",[305,306,307,308,309,29],"Anxiety Disorders","Stress Disorders, Post-Traumatic","Pregnancy, High Risk","Depressive Disorder, Major","Pregnancy Complications",[311,312,298,313,314,315],"Collaborative Mental Health Care Program","Inpatient high-risk pregnancy support","High-risk pregnancy mental health","Perinatal psychotherapy","Trauma-informed therapy","2026-04-18",{"date":318,"type":43},"2026-04-22",{"date":320,"type":22},"2026-06-01",{"date":322,"type":22},"2027-06-01",{"name":324,"class":50},"Indiana University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":332,"maxAge":19,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":51},"100583066","phase-4-predictors-of-improvements-in-irritability-and-aggression-in-children-with-adhd-treated-with-cns-stimulants-100583066","NCT06871488","Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants","Identification of Neural Markers of Aggression and Irritability and Their Capacity to Predict Treatment Response to CNS Stimulant Medication in Youth With ADHD","Inclusion Criteria:\n\n1. Meet criteria for any presentation of ADHD\n2. Moderate or worse impairment related to ADHD\n3. Elevated levels of irritability and\u002For aggression on guardian ratings of Affective Reactivity Index and Retrospective Modified Overt Aggression Scale\n4. fluent in English for child and guardian\n5. Guardian and child are willing to have child take CNS stimulant medication for ADHD\n\nExclusion Criteria:\n\n1. Medical contraindications to use of CNS stimulants\n2. Autism Spectrum Disorder,\n3. Bipolar Disorder,\n4. Intellectual\u002FDevelopmental Delay\n5. current use of antipsychotic, mood stabilizing\n6. Use of other medications that impact EEG data collection (e.g. benzodiazepenes)\n7. hearing or visual deficits that impede ability to do computer tasks\n8. Current Major Depressive Episode\n9. Current suicidal ideation\n10. child has failed two fully optimized trials of methylphenidate products AND two for amphetamine products","7 Years",{"count":334,"type":22},136,[226],"Impulsive Aggression and chronic irritability (IACI) often occur together and are one of the most common reasons children present for behavioral health (BH) care. ADHD frequently associated with IACI as upwards of 50% of youth with ADHD manifest impairing IACI levels. IACI is the most common reason that children with ADHD are prescribed antipsychotics and admitted to inpatient BH units. Systematic dose optimization of CNS stimulants improves levels of IACI, reducing the need for these more intensive and burdensome treatments. However, response varies, with over half of children with ADHD showing meaningful improvement, upwards of 40% receiving minimal benefit and 3 to 10% exhibiting increased IACI levels. Symptom levels of ADHD or IACI and other demographic variables are of limited utility for predicting response, suggesting the need to move beyond symptoms in the search for treatment predictors. Youth with ADHD and IACI struggle with multiple aspects reinforcement learning (RL), defined as learning from interactions with the environment to reach a goal. Successful RL efforts tap multiple cognitive functions. In controlled laboratory tasks, youth with IACI and various BH disorders exhibit excessive behavioral and neural response to receiving reward (reward responsiveness), difficulty processing environmental cues to adapt behavior to meet a goal (set shifting\u002Fgoal updating) and impaired ability to flexibly attend to relevant stimuli when blocked from a goal (frustrative nonreward). Event related potentials (ERP) are small electrical responses in the brain in response to specific events or stimuli measured by electroencephalogram (EEG) testing. ERPs exist that can serve as established neural measures of each of these cognitive functions offering a child friendly means to assess their contribution to observable levels of IACI.\n\nCNS stimulants improve functioning in these specific realms and impact associated ERPs to the degree that differences between ADHD and non-ADHD youth disappear. This study will examine the capacity of these ERPs to predict levels of IACI exhibited by children with ADHD when at home. Investigators will then assess if variability across children in the capacity of CNS stimulants to impact RL associated ERPs accounts for differences in the clinical effects of CNS stimulant medications to improve IACI at home using a multimethod battery integrating ERPs, parent report and task performance. Specifically, investigators will examine variance in the reward positivity (RewP) ERP when receiving reward feedback, the switch positivity (SwP) ERP measuring mental effort when cued to shift set and the change in P3b amplitude measuring attention allocation when transitioning from reward to nonreward on a go-no-go task. To achieve these aims, 136 children with ADHD and elevated IACI levels will have their CNS stimulant dose optimized over six weeks and then complete a two week within subjects crossover trial of placebo versus optimal dose. ERP collection will be completed within each blinded week. Parent ratings will be gathered 3 times per day including during peak and off-peak times of medication efficacy to capture the variance in IACI levels within the day and disentangle reports of worsening IACI related to loss of previously beneficial medication effects versus those most likely related to a direct adverse response to medication.",[29,338,339],"Irritability","Aggression Childhood",[35,341,338,342],"CNS Stimulants","Aggression","2026-04-15",{"date":345,"type":43},"2026-04-20",{"date":347,"type":43},"2026-03-05",{"date":349,"type":22},"2030-06-30",{"name":351,"class":50},"Milton S. Hershey Medical Center",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":359,"maxAge":172,"enrollmentInfo":360,"targetDuration":362,"studyType":146,"phases":4,"briefSummary":363,"conditions":364,"keywords":372,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":51},"100567463","magnetoencephalography-in-children-100567463","NCT06668519","Magnetoencephalography in Children","An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\n1. aged 1 month-18 years old (date of investigate minus date of birth)\n2. epilepsy\n3. intracranial tumors\n4. cerebrovascular diseases\n5. autism\n6. mental retardation\n7. ADHD\n8. tic disorder\n9. neuropsychiatric disorders\n\nExclusion Criteria:\n\n1.Unable to cooperate with the exam of MEG","1 Month",{"count":361,"type":22},1500,"3 Years","This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.",[365,366,367,71,29,368,369,370,371],"Epilepsy","Intracranial Tumors","Cerebrovascular Disease","Neuropsychiatric Disorders","Tic Disorder, Childhood","Mental Retardation","Developmental Disabilities",[373,374,375],"neurodevelopmental diseases","magnetoencephalography","pediatric","2026-03-24",{"date":378,"type":43},"2026-03-25",{"date":380,"type":43},"2024-09-25",{"date":382,"type":22},"2027-12-30",{"name":384,"class":50},"Children's Hospital of Fudan University",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":60,"sex":17,"minAge":392,"maxAge":172,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":408},"100629729","adris-driving-simulator-for-adolescents-with-attention-deficit-and-hyperactivity-disorder-100629729","NCT07478458","ADRIS Driving Simulator for Adolescents With Attention Deficit and Hyperactivity Disorder","ADRIS-ADHD","Inclusion Criteria for ADHD subjects:\n\n* Age range 13-18 years (up to the age of nineteen)\n* Diagnosis of ADHD (hyperactive, inattentive and combined subtype)\n* Consent to participate in the study by the participant or, in the case of a minor, by their parent(s)\u002Fguardian(s).\n\nInclusion Criteria for Control Group subjects:\n\n* Age- and sex-matched neurotypical adolescents\n* No diagnosis of ADHD or other neurodevelopmental disorders\n* Informed consent obtained from the participant if of legal age or from the legal guardian and assent from the minor\n\nExclusion Criteria:\n\n* Visual deficits not corrected\u002Fcorrectable with the normal use of lenses.\n* Motor deficits clinically detected and\u002For previously diagnosed and that could compromise the use of the simulator (e.g. neurological diseases, psychiatric diseases, etc.).\n* Categorical diagnoses according to DSM-5 criteria such as Psychosis, Mood Disorders, Autism Spectrum Disorders, Intellectual Disabilities, Borderline Intellectual Functioning, Anxiety Disorders.\n* Patients with other conditions that could affect driving ability.\n* Denial \u002F withddrawal of consent to the protocol","13 Years",{"count":21,"type":22},[25],"This study aims to evaluate a new driving simulator, called ADRIS 2.1, developed for adolescents aged 13-18 years with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common neurodevelopmental disorder that can affect attention, self-control, and decision-making. These challenges may impact daily activities, including driving.\n\nThe ADRIS simulator allows participants to \"drive\" in a virtual environment while their performance is monitored. The system measures driving errors (such as not stopping at red lights), head and body movements, and heart rate, helping researchers understand how ADHD may affect driving-related behavior.\n\nParticipants in the study will include both adolescents with ADHD and typically developing adolescents. All participants will complete standardized cognitive and behavioral assessments and take part in at least one driving simulation session. Adolescents with ADHD will return for follow-up visits and a subgroup will participate in a 6-week training program using the simulator.\n\nThe main goal of the study is to measure differences in driving performance and attention between adolescents with and without ADHD. The study will also explore whether the simulator can detect improvements over time and in response to clinical treatment or simulator-based training.\n\nThe results may help inform future clinical evaluations and support tools for adolescents with ADHD, with the potential to improve safety and quality of life.",[29],[35,398],"Driving simulator","2026-03-13",{"date":401,"type":43},"2026-03-17",{"date":403,"type":43},"2025-11-10",{"date":405,"type":22},"2028-01",{"name":407,"class":50},"Istituto Giannina Gaslini",2,{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":332,"maxAge":61,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":51},"100566471","external-trigeminal-nerve-stimulation-for-attention-deficit-hyperactivity-disorder---feasibility-trial-100566471","NCT06655610","External Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder - Feasibility Trial","External Trigeminal Nerve Stimulation Versus Sham Stimulation for Attention Deficit Hyperactivity Disorder in Children and Adolescents Aged 7-17 Years: Study Protocol for a Pilot and Feasibility Randomized Clinical Trial","eTNS4ADHD","Inclusion Criteria:\n\n* 7 to 17 years of age at the time of study enrollment.\n* A clinical diagnosis of ADHD according to criteria for ICD-10: F90.0, F91.0, F90.8, F90.9, F98.8C. The ADHD diagnosis must be verified by the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) using The Schedule for Affective Disorders and Schizophrenia for School-aged Children (K-SADS).\n* A score above 24 on the ADHD rating scale (ADHD-RS) at baseline.\n* Signed informed consent from parents\u002Flegal caretakers and from the patients aged ≥ 15.\n\nWe will include treatment-naïve patients, patients who previously have received stimulant medication, and patients in stable, ongoing stimulant medication (methylphenidate or dexamphetamines\u002Flisdexamphetamine) during the time of the trial.\n\nExclusion Criteria:\n\n* Patients receiving atomoxetine and guanfacine at the time of study enrollment will be excluded all together\n* Epilepsy\n* Electronic or metallic implants.\n* Serious mental and\u002For somatic diseases other than ADHD, such as:\n\n  * Pervasive developmental disorder not including Asperger's syndrome (ICD-10 F84.0-84.4 + F84.8-84.9)\n  * Schizophrenia\u002Fparanoid psychosis (ICD-10 F20-25 + F28-29)\n  * Mania or bipolar disorder (ICD-10 F30 and F31)\n  * Depressive psychotic disorders (ICD-10 F32.3 + F33.3)\n  * Substance dependence syndrome (ICD-10 F1x.2)\n  * Cardio-vascular disorders\n  * Cancer\n* An Intelligence quotient (IQ) below 70 measured by the Wechsler Intelligence Scale for Children\n* A substantial degree of restless sleep as reported by parents or caregivers and evaluated by the physician.\n* Other disabilities that may make use of Monarch problematic.",{"count":418,"type":22},60,[25],"The investigators will assess the use of the Monarch eTNS device as a non-pharmacological treatment for patients aged 7 to 17 years with ADHD.\n\nThe investigators will compare the eTNS device to a sham device. Participants will use the device for four weeks during night time. During the trial, participants will receive different questionaires to assess symptoms and will also keep a logbook to record their experience with the device.\n\nAt the end of trial, the investigators will assess what the families thought of the device, and whether it is indeed feasible to further explore the effect of the device in a larger clinical trial.",[29],[35,423,424,425],"Neuromodulation","External trigeminal nerve stimulation","feasibility trial",{"date":427,"type":43},"2026-03-09",{"date":429,"type":43},"2024-12-05",{"date":431,"type":22},"2026-11-25",{"name":433,"class":50},"Psychiatric Research Unit, Region Zealand, Denmark",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":300,"minAge":172,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":51},"100626607","psychophysiological-responses-to-six-single-session-self-regulation-interventions-in-a-female-adult-with-adhd-and-stabilized-bipolar-disorder-100626607","NCT07437833","Psychophysiological Responses to Six Single-Session Self-Regulation Interventions in a Female Adult With ADHD and Stabilized Bipolar Disorder","Psychophysiological Responses to Six 15-Minute Single-Session Self-Regulation Interventions in a Female Adult With ADHD and Stabilized Bipolar Disorder: A Single-Case Study","Inclusion Criteria:\n\n* Diagnosis of ADHD and bipolar disorder (type I or II) in stable remission.\n* No active depressive, manic, or psychotic episodes for at least 2 years.\n* No use of psychotropic medications, including mood stabilizers, antidepressants, antipsychotics, or ADHD medications, for at least 2 years.\n* No chronic somatic diseases (including neurological, cardiovascular, or metabolic disorders).\n* Regular sleep-wake rhythm during the week preceding the study.\n* Non-smoker.\n* No night-shift work in the week preceding the study.\n\nExclusion Criteria:\n\n* Acute medical conditions that could affect study procedures.\n* Use of medications in the past 3 months that influence cardiovascular or neurological parameters.\n* Consumption of alcohol or psychoactive substances on the day before or day of the study.\n* Intense physical activity on the day before or day of the study.\n* Contraindications to moderate-intensity exercise on a cycle ergometer (e.g., recent injuries, chronic musculoskeletal conditions).\n* Contraindications to EEG measurement (e.g., scalp skin conditions preventing proper electrode placement, hypersensitivity to conductive gels or pastes).","35 Years",{"count":51,"type":22},[25],"This study aims to explore how six short, 15-minute self-regulation techniques affect the body and brain in a female adult with ADHD and stabilized bipolar disorder. The techniques being tested include:\n\n* Aerobic exercise\n* Controlled breathing (cyclic sighing)\n* Aromatherapy with lavender essential oil\n* Listening to specific music (Solfeggio 528 Hz)\n* Virtual reality relaxation with forest imagery\n* Emotional Freedom Technique (EFT) tapping One session of quiet sitting with eyes open serves as a comparison.\n\nThe participant will attend one 15-minute session per week for each technique. Before and after each session, the researchers will measure:\n\n* Heart rate and heart rate variability\n* Stress levels using Subjective Units of Distress Scale\n* Mood using a questionnaire\n* Blood pressure\n* Brain activity using EEG\n* Memory performance with a simple test (N-back)\n* Pain sensitivity The goal is to understand how these short, non-invasive techniques influence both physiological and psychological responses. Sessions are safe, short, and designed to involve minimal risk. The findings may help guide future research on relaxation and exercise strategies for people with ADHD and bipolar disorder.",[29,446],"Bipolar Affective Disorder; Remission in","2026-02-23",{"date":449,"type":43},"2026-02-27",{"date":451,"type":22},"2026-04-01",{"date":453,"type":22},"2026-08-31",{"name":455,"class":50},"Poznan University of Physical Education",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":60,"sex":17,"minAge":332,"maxAge":61,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100625072","study-of-the-nutritional-inflammatory-and-metabolic-endophenotypes-of-attention-deficithyperactivity-disorder-adhd-100625072","NCT07417878","Study of the Nutritional, Inflammatory, and Metabolic Endophenotypes of Attention-Deficit\u002FHyperactivity Disorder (ADHD)","ANIME","ADHD Group (Cases) - Inclusion Criteria:\n\n* Children or adolescents aged 7 to 17 years.\n* Meet DSM-5 diagnostic criteria for Attention-Deficit\u002FHyperactivity Disorder (ADHD), assessed using the K-SADS interview.\n* Currently treated with psychostimulant medication.\n* Stabilized on psychostimulant treatment for at least one month prior to inclusion.\n* Signed informed consent obtained from parents or legal guardians.\n* Assent obtained from the minor participant.\n* Affiliation with a national health insurance system.\n\nControl Group (Typically Developing Peers) - Inclusion Criteria:\n\n* Children or adolescents aged 7 to 17 years without any diagnosed mental disorder.\n* Age- and sex-matched with the ADHD group.\n* Signed informed consent obtained from parents or legal guardians.\n* Assent obtained from the minor participant.\n* Affiliation with a national health insurance system.\n\nADHD Group (Cases) - Exclusion Criteria:\n\n* Presence of a progressive neurological disorder, intellectual developmental disorder, or clinically significant suicide risk.\n* Presence of an immunological or chronic inflammatory disease.\n* Inability to comply with medication-free periods of at least two weeks.\n* Absence of parental consent.\n* Absence of assent from the minor participant.\n* Participation in another clinical study with an ongoing exclusion period.\n\nControl Group (Typically Developing Peers) - Exclusion Criteria:\n\n* Presence of an immunological or chronic inflammatory disease.\n* Absence of parental consent.\n* Absence of assent from the minor participant.\n* Participation in another clinical study with an ongoing exclusion period.",{"count":464,"type":22},80,[25],"This study aims to better understand the biological mechanisms involved in attention deficit hyperactivity disorder (ADHD) and to clarify why some children and adolescents respond well to methylphenidate (MPH)-the most commonly prescribed medication-while others do not. Although MPH is effective for many patients, a significant number experience limited benefits or problematic side effects such as appetite loss and sleep difficulties. Recent research suggests that inflammation and oxidative stress in the body may play an important role in ADHD. Some animal studies also indicate that MPH itself might trigger inflammatory processes, but this has never been examined directly in humans.\n\nThe main goal of this research is to determine whether children with ADHD show differences in their nutritional, immune, and inflammatory profiles compared to children without ADHD, and whether these biological factors influence symptom severity, digestive problems, and response to treatment. The study also seeks to understand whether MPH has a measurable inflammatory effect in young patients and whether this could be linked to treatment tolerability.\n\nTo answer these questions, the study combines several approaches. First, a case-control comparison will examine differences between children\u002Fadolescents with ADHD and age- and sex-matched controls. Second, a one-year follow-up of the ADHD group will evaluate changes over time and help identify biological predictors of treatment response and side effects. Finally, a cross-sectional analysis will investigate the role of polyphenols-natural antioxidant compounds found in food-in relation to inflammation, treatment outcomes, and gender differences.\n\nThe primary focus is on comparing levels of the inflammatory marker IL-6 between children with ADHD and controls. Secondary objectives include assessing additional inflammatory and immune indicators, nutritional status, gastrointestinal symptoms, ADHD severity, irritability, and MPH tolerability.\n\nBy identifying specific inflammatory and immune markers associated with ADHD and treatment response, this study hopes to improve understanding of the disorder and guide more personalized and effective treatment strategies for young patients. It will also provide the first human data on whether psychostimulant medications may have inflammatory effects.",[29],[35,469,470,471,472,473,474],"Neurodevelopmental Disorders","Psychostimulant","Inflammation","Interleukin-6 (IL-6)","Polyphenols","Cytokines","2026-02-13",{"date":477,"type":43},"2026-02-18",{"date":479,"type":22},"2026-03",{"date":481,"type":22},"2029-03",{"name":483,"class":50},"University Hospital, Montpellier",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":60,"sex":17,"minAge":247,"maxAge":172,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":51},"100619175","how-virtual-reality-can-help-neurodivergent-children-improve-their-attention-100619175","NCT07341204","How Virtual Reality Can Help Neurodivergent Children Improve Their Attention","Improvement of Sustained Attention Through Immersive Virtual Reality in Neurodivergent Children","Attend-VR","Inclusion Criteria:\n\n* Clinical diagnosis of ASD, ADHD, SLD, or DCD confirmed by a licensed clinician or documented in medical\u002Feducational records (DSM-5 or equivalent).\n* Parent\u002Fguardian consent and participant assent (age-appropriate).\n* Ability to follow simple verbal instructions and to participate in 25-minute VR sessions twice weekly for 6 weeks.\n* Stable medication regimen for attention- or behavior-related medications for ≥4 weeks prior to baseline (or not taking such medications).\n* Visual and auditory ability adequate for VR tasks (with or without usual corrective lenses\u002Fhearing aids).\n* Availability to attend all scheduled sessions at the clinical site across the 6-week period.\n\nExclusion Criteria:\n\n* History of photosensitive epilepsy or any uncontrolled seizure disorder.\n* Severe intellectual disability or severe communication impairment that prevents understanding\u002Fparticipation (e.g., non-responsive to simple commands required by the VR tasks).\n* Severe visual, auditory, or motor impairment that prevents safe or functional use of the VR system (e.g., inability to hold controllers or view the headset even with correction).\n* Recent (within 6 months) significant brain injury or neurosurgery. Significant history of motion sickness, severe vestibular disorder, or prior intolerance to immersive VR.\n* Any medical or implanted device contraindicated for VR\u002Fheadset use (if applicable).",{"count":493,"type":22},40,[25],"The goal of this study is to determine whether playing a virtual reality (VR) game can help neurodivergent children pay attention for extended periods. The study includes children ages 9 to 18 who have autism, ADHD, learning differences, or movement coordination challenges. The program lasts for 6 weeks. During this period, children will play a VR game twice per week, with each session lasting 25 minutes.",[71,70,29,497],"Attention Deficit Disorder",[499,500,501,502,503,504],"attention","impulsivity","distractability","focus","VR","Immersive Virtual Reality","2026-01-06",{"date":507,"type":43},"2026-01-14",{"date":509,"type":22},"2026-02-02",{"date":511,"type":22},"2026-04-06",{"name":513,"class":50},"New York Institute of Technology",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":17,"minAge":392,"maxAge":61,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":526,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":408},"100614553","comparative-efficacy-of-organizational-skills-training-ost-and-mindfulness-based-intervention-mbi-100614553","NCT07281092","Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)","Comparing Psychosocial Supports for Adolescents With ADHD: What Works Best for Whom and Why?","Inclusion Criteria:\n\n* Adolescent between the ages of 13-17 years\n* Pre-existing diagnosis of ADHD in medical record\n* Seeking treatment at the Seattle Children's Hospital BAM Clinic\n\nExclusion Criteria:\n\n* Psychiatric comorbidity that interferes with treating ADHD as the presenting concern per the study team.\n* Other concerns besides ADHD that would interfere with study participation according to the study team.",{"count":522,"type":22},36,[25],"This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program.\n\nBoth treatments are eight 90 minute sessions.\n\nThe research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.",[35,29],[527,528],"adhd","attention deficit hyperactivity disorder","2025-12-08",{"date":531,"type":43},"2025-12-15",{"date":533,"type":43},"2025-10-01",{"date":131,"type":22},{"name":536,"class":50},"Seattle Children's Hospital",{"id":538,"slug":539,"hasResults":11,"nctId":540,"briefTitle":518,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":60,"sex":17,"minAge":392,"maxAge":61,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":524,"conditions":546,"keywords":547,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":51},"100599842","comparative-efficacy-of-organizational-skills-training-ost-and-mindfulness-based-intervention-mbi-100599842","NCT07089745","Pilot Comparative Efficacy Randomized Controlled Trial of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) for Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD).","Inclusion Criteria:\n\n* Adolescent between the ages of 13-17 years\n* Pre-existing diagnosis of ADHD in medical record\n* Seeking treatment at the Duke ADHD Program\n\nExclusion Criteria:\n\n* Psychiatric comorbidity that interferes with treating ADHD as the presenting concern per the study team.\n* Other concerns besides ADHD that would interfere with study participation according to the study team.",{"count":544,"type":22},30,[25],[35,29],[527,528],"2025-10-16",{"date":550,"type":43},"2025-10-20",{"date":552,"type":43},"2025-09-18",{"date":554,"type":22},"2026-09",{"name":264,"class":50},{"id":557,"slug":558,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":60,"sex":17,"minAge":197,"maxAge":172,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":572,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":408},"100608585","where-wild-things-grow-nature--and-activity-based-group-interventions-for-neurodivergent-children-and-youth-100608585","NCT07203469","Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth","Where Wild Things Grow: Immediate and Long-term Impact of Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth in School, Health Care and Leisure Settings in Agder","Inclusion Criteria:\n\n* In PhD 1, participants are recruited on class-level (all) or individual (identified need).\n* In PhD 2, inclusion criteria are patients that participate in the specific interventions.\n\nExclusion Criteria:\n\n* In PhD 2, exclusion criteria include substance misuse, acute psychosis, current suicidal behavior\u002Fideation, and severe eating disorders.",{"count":564,"type":22},240,[25],"The goal of this action research project is to develop and implement nature- and activity-based group interventions across health care, school and leisure settings in Southern Norway. The interventions are tailored to support the mental health, self-efficacy and daily life functioning of children and youth in the Agder region, with a particular focus on youngsters who struggle due to neurodivergence, such as Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) or Tourette's syndrome.\n\nThe main questions we aim to answer are:\n\n1. To what extent does nature- and activity-based outdoor education contribute to improvements in children's quality of life?\n2. To what extent does nature- and activity-based interventions in a health care setting improve children's self-efficacy, self-esteem and quality of life?\n3. Is there a difference in physiological reactions between nature-based provision of education or therapy and traditional indoor provision of education or therapy?\n\nParticipants will take part in a 12-week school-based or health care intervention.",[568,29,71,569,570,571],"Neurodevelopmental Outcomes","Tourette Syndrome","Health-Related Quality-of-Life","Heart Rate Variability (HRV)",[573,574,575,35,71,576,577,578,579],"Nature-based","Action research","child and adolescent mental health","Health-related quality of life","outdoor therapy","experiential education","heart rate variability",{"date":581,"type":43},"2025-10-02",{"date":583,"type":43},"2025-09-01",{"date":585,"type":22},"2027-06-15",{"name":587,"class":588},"Sorlandet Hospital HF","OTHER_GOV",{"id":590,"slug":591,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":17,"minAge":597,"maxAge":332,"enrollmentInfo":598,"targetDuration":332,"studyType":146,"phases":4,"briefSummary":600,"conditions":601,"keywords":606,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":51},"100603447","speech-of-kids-after-neonatal-encephalopathy-100603447","NCT07136636","Speech of Kids After Neonatal Encephalopathy","Investigating the Prognostic Accuracy of Different Biomarkers for Detection of Developmental Language Disorder in Children With Neonatal Encephalopathy","SANE","Children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelweis University Children's Hospital.\n\nInclusion criteria\n\n1. Born at ≥ 35th week of gestation\n2. Attended follow-up examinations at two years of age\n3. Has parental informed consent\n\nExclusion criteria\n\n1. Hearing loss\n2. Multilingual language environment\n3. Congenital abnormalities\n4. Metabolic disease\n5. Sudden unexpected postnatal collapse\n6. Brain injury not caused by HIE\n7. Severe motor impairment defined as a score \\\u003C70 on the psychomotor development index (PDI) at 2 years of age","0 Years",{"count":599,"type":22},93,"The goal of this ambispective cohort study is to reveal the early indicators of delayed language development in children born with hypoxic-ischemic encephalopathy (HIE).\n\nWe will examine the prognostic accuracy of different biomarkers, with a special focus on the ADC values of the corpus callosum.\n\nThe main questions it aims to answer are:\n\n1. To what extent does hypoxic-ischemic encephalopathy (HIE) in infancy affect intellectual development (IQ), receptive and expressive language abilities at different levels of the language system, and memory capacities related to language development?\n2. What is the relationship between early biomarkers of brain injury-such as blood gas levels, lactate, aEEG, and MRI findings (Weeke scoring system, ADC values of the corpus callosum)-and long-term cognitive developmental outcomes?\n3. What is the incidence of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in this high-risk population of infants with HIE?\n4. Is there an association between the Weeke Total Score and long-term language developmental outcomes?\n5. Can restricted diffusion (ADC values) of the splenium of the corpus callosum serve as an early neuroradiological marker of developmental language disorder (DLD)?\n\nOur participants are children born between 2017 and 2023 with moderate to severe HIE, treated with therapeutic hypothermia at Semmelwies University Children's Hospital. During their first days of life, several neonatal measurements were taken (blood gas markers, aEEG etc.), and at day 4-5, they had an MRI scan of their brain. The MRI scans will be reanalyzed, using the Weeke MRI scoring system. These children underwent a neurodevelopmental follow-up at the age of 2 years and currently, they will have another follow-up at the age of 4-7 years.",[602,603,71,29,604,605],"HIE - Hypoxic - Ischemic Encephalopathy","Language Delay","Specific Language Impairment","Intellectual Developmental Disorder",[602,607,608,609,610,611,612,613],"delayed language development","neurodevelopment","MRI","biomarker","corpus callosum diffusion restriction","IQ","newborn prediction tool","2025-08-14",{"date":616,"type":43},"2025-08-22",{"date":618,"type":43},"2025-04-01",{"date":620,"type":22},"2026-12",{"name":622,"class":50},"Semmelweis University",{"id":624,"slug":625,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":634,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":408},"100568774","an-intervention-study-on-transcranial-photobiomodulation-in-children-with-attention-deficit-hyperactivity-disorder-100568774","NCT06685601","An Intervention Study on Transcranial Photobiomodulation in Children With Attention Deficit Hyperactivity Disorder","An Intervention Study on Transcranial Photobiomodulation for Children With Attention-Deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\n1. Age between 6 and 18 years;\n2. Clinically diagnosed with ADHD by a psychiatrist;\n3. Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit\u002FHyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);\n4. M.I.N.I. KID interview shows only ADHD, with no other comorbidities;\n5. Able to cooperate with transcranial photobiomodulation.\n6. The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form.\n\nExclusion Criteria:\n\n1. Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder;\n2. Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.;\n3. Presence of significant structural brain abnormalities on imaging studies;\n4. Presence of severe neurological diseases with a clear family history or potential risk;\n5. Presence of metal implants or a pacemaker, or holes or fractures in the skull;\n6. Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks;\n7. Raven's Progressive Matrices IQ score \\\u003C 85.",{"count":418,"type":22},[25],"This study aims to intervene in children and adolescents with ADHD using transcranial photobiomodulation, comparing its effects on executive function at the levels of electroencephalography (EEG), eye tracking, and cognitive behavior. The goal is to identify the most effective clinical treatment strategy for ADHD patients.",[29],[635,35],"tPBM","2025-07-20",{"date":638,"type":43},"2025-07-22",{"date":640,"type":43},"2024-12-16",{"date":642,"type":22},"2027-05",{"name":644,"class":50},"Qilu Hospital of Shandong University",{"id":646,"slug":647,"hasResults":11,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":11,"sex":17,"minAge":652,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":23,"phases":655,"briefSummary":656,"conditions":657,"keywords":661,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":672,"leadSponsor":674,"locationsCount":51},"100586071","exploring-parameters-of-driving-simulation-in-relation-to-drug-holidays-in-adhd-patients-100586071","NCT06910605","Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients","DS-ADHD1","Inclusion criteria:\n\n* adult drivers\n* ADHD-diagnosed, established ADHD-treatment only with stimulants\n* known history of drug holidays based on own decision,\n* at impaired eyesight with more than +\u002F- 5 diopter or astigmatism\n* contact lenses are required (for eye tracking)\n\nExclusion criteria:\n\n* sensibility to motion sickness (kinetosis, dizziness etc. in 5 min screening drive)\n* non-stimulant-treatment\n* inability to understand the study procedure for linguistic or cognitive reasons\n* professional drivers (if working during the study period)\n* for women: pregnancy","10 Years",{"count":654,"type":22},26,[25],"Attention deficit hyperactivity disorder (ADHD) or syndrome (ADHS) is a symptomatically defined condition that - if untreated - is linked to a significantly increased risk of traffic accidents. In a recent umbrella review, where data from reviews and meta-analyses on 21.142.129 adults was assessed, a pooled prevalence of 3.1% of ADHD in adults was estimated. Considering that globally around 1.35 million people lose their lives and more than 50 million are suffering from injuries or disabilities due to road accidents, the fraction of car accidents caused by ADHD as a risk factor is considerable and needs to be addressed. This risk is largely presumed to be caused by an elevated level of inattentiveness in affected persons.\n\nCompounds of different groups, which can be classified in stimulants - formulations of methylphenidate and amphetamine - and non-stimulants - atomoxetin, guanfacine and clonidine -, have been shown to be effective in alleviating negative effects of ADHD, including inattentiveness. Under well-established but individually managed medication regimes, affected individuals can consequently lead a largely \"unirritated\" life and are not subject to fundamental restriction with respect to driving anymore.\n\nIn children and adolescents, documented negative effects of stimulant medication include loss of appetite and decreased growth rates. It could however be shown that short-term interruptions (weekend, school holidays, and alike), introduced to alleviate aforementioned effects, do not affect the drug's beneficial effects in functional use (e.g., school). Such monitored medication breaks are often called \"drug holidays\" (D). They have become standard procedure in well-monitored treatment, predominantly including behavioral therapy.\n\nBased on own experience in childhood and or hearsay, also a fraction of affected adults under stimulant medication expresses the desire to take drug holidays and \"be themselves\" from time to time. With the predominant fraction of medication being fast acting drugs in extended-release formulation and typical patients being not only highly compliant but also extremely informed and adherent, these so-called \"drug holidays\" are reported an accepted in therapeutically accompanied settings of adults by now.\n\nHowever, while the overall positive effect of stimulant treatment on driving performance has been confirmed in a row of excellent on road- and\u002For simulation studies using integrated driving scores (IDS), so far there is no study available addressing the effect of drug holidays in adult drivers on driving performance. This represents a significant gap of evidence for both medical experts and affected.\n\nThe proposed study will address this gap by exploring parameters of driving simulation in relation to drug holidays in ADHD patients.",[29,658,35,659,660],"Driving Simulator Performance","Driving Behavior","Driving Ability",[662,663,664,665,666,667],"driving simulation","driving performance","eye tracking","EEG-recording","stimulant treatment","drug holidays","2025-06-02",{"date":670,"type":43},"2025-06-05",{"date":668,"type":43},{"date":673,"type":22},"2026-10-31",{"name":675,"class":50},"Stefan Lakämper",{"id":677,"slug":678,"hasResults":11,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":392,"enrollmentInfo":683,"targetDuration":4,"studyType":23,"phases":684,"briefSummary":685,"conditions":686,"keywords":687,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":696,"locationsCount":408},"100585287","sustained-endogenous-attention-deficits-in-attention-deficit-hyperactivity-disorder-100585287","NCT06900400","Sustained Endogenous Attention Deficits in Attention Deficit Hyperactivity Disorder","Evaluation of Sustained Endogenous Attention Deficits in Attention Deficit Hyperactivity Disorder: Validation of a Computerized Neuropsychological Test.\"","Inclusion Criteria:\n\n* ADHD Group (1) Subjects with a diagnosis of ADHD of any severity level and subtype\n* ADHD Group (2) \"Medication-naive\" ADHD subjects, meaning subjects who have not been prescribed and\u002For have not yet started any pharmacological treatment for ADHD\n* ADHD Group (3) IQ ≥ 70\n* Non-ADHD Group, Normal IQ\n\nExclusion Criteria:\n\n* for both groups, symptomatology suggestive of autism spectrum disorders, psychotic disorders, mood disorders, and anxiety disorders\n* for both groups, use of psychotropic drugs\n* for both groups, subjects with cerebral palsy and\u002For neuromotor and neuromuscular disorders\n* for both groups, CNS diseases, e.g., epilepsy and\u002For neurodegenerative diseases, or central nervous system injuries resulting from, for example, head trauma or stroke\n* for the non-ADHD group, presence of ADHD symptoms",{"count":302,"type":22},[25],"Subjects with ADHD may exhibit deficits in sustained internal attention. The \"Sustained-Paced Finger Tapping\" test was recently developed and experimentally used in international literature to assess sustained internal attention in typically developing children. This clinical study has several objectives: 1) to assess the presence of \"internal\" sustained attention deficits in children with ADHD through the \"Sustained-Paced Finger Tapping\"; 2) to evaluate the discriminant and ecological validity of the \"Sustained-Paced Finger Tapping.\"",[29],[688,689,35],"Case control","diagnostic","2025-03-27",{"date":692,"type":43},"2025-03-28",{"date":694,"type":43},"2024-11-11",{"date":235,"type":22},{"name":697,"class":50},"IRCCS Eugenio Medea"]